Sharma V. Ryanodine receptor 2 mutations in catecholaminergic polymorphic ventricular tachycardia: From molecular mechanisms to precision medicine. World J Cardiol 2026; 18(2): 111032 [DOI: 10.4330/wjc.v18.i2.111032]
Corresponding Author of This Article
Vaibhav Sharma, MD, Resident Physician, Internal Medicine, Medstar Washington Hospital Center, Washington, DC 20010, United States. vsharma3090@gmail.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Feb 26, 2026 (publication date) through Feb 9, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Cardiology
ISSN
1949-8462
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Sharma V. Ryanodine receptor 2 mutations in catecholaminergic polymorphic ventricular tachycardia: From molecular mechanisms to precision medicine. World J Cardiol 2026; 18(2): 111032 [DOI: 10.4330/wjc.v18.i2.111032]
World J Cardiol. Feb 26, 2026; 18(2): 111032 Published online Feb 26, 2026. doi: 10.4330/wjc.v18.i2.111032
Ryanodine receptor 2 mutations in catecholaminergic polymorphic ventricular tachycardia: From molecular mechanisms to precision medicine
Vaibhav Sharma
Vaibhav Sharma, Internal Medicine, Medstar Washington Hospital Center, Washington, DC 20010, United States
Author contributions: Sharma V conceived and designed the study, conducted the comprehensive literature search, performed data synthesis and analysis, drafted the manuscript, created all figures and tables, and critically revised the manuscript for important intellectual content. The author takes full responsibility for the integrity of the work and the accuracy of the data analysis.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Vaibhav Sharma, MD, Resident Physician, Internal Medicine, Medstar Washington Hospital Center, Washington, DC 20010, United States. vsharma3090@gmail.com
Received: June 23, 2025 Revised: August 1, 2025 Accepted: December 17, 2025 Published online: February 26, 2026 Processing time: 233 Days and 7.1 Hours
Core Tip
Core Tip: Catecholaminergic polymorphic ventricular tachycardia serves as a paradigm of precision cardiology in which a mechanistic unravelling of the ryanodine receptor 2-mediated calcium ion channel abnormality helps in formulating a genotype-oriented treatment approach. Recent studies regarding the pathopharmacology of store overload-induced calcium ion release, together with mitochondrial interactions, posit the possibility of a more complex pathophysiology than the classic electrical disorders. Recent milestones in the application of the clustered regularly interspaced short palindromic repeats gene editing tool together with artificial intelligence-assisted diagnostic techniques in association with a personalized form of pharmacotherapy have resulted in the successful treatment of 80%-90% of the affected subjects.
